$121.51▾ 0.25%
End-of-day close · 2026-09-01
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
Not enough data yet
Not enough revenue history to measure growth.
Leverage
Not enough data yet
More coming: dilution / share-count creep.
✦ The read
Insmed Incorporated's earnings-quality signal is not available yet.
Key numbers
Recent news
Sentiment · last 30 days1 article
1 bullish0 neutral0 bearish
FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce
LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now?Nontuberculous Mycobacterial Infections Market to Showcase Growth at a CAGR of 12.6% During the Forecast Period (2026–2036), Driven by Rising Disease Burden and Emerging Therapies | DelveInsight
- Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?
Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?